# A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

> **NCT05753865** · PHASE3 · UNKNOWN · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 454 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** SYHX2011
- **DRUG:** Paclitaxel for injection (albumin-bound)

## Key facts

- **NCT ID:** NCT05753865
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 454 (ESTIMATED)
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753865, "A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05753865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*